Company / Cash & Equivalents
Caris Life Sciences, Inc. Cash & Equivalents History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$796.3M
FY2025
5-year range
$796.3M / $796.3M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#33 of 148
Health Care
What the data says
Caris Life Sciences, Inc.'s cash & equivalents of $796M is higher than 78% of companies in the Health Care sector (FY2025).
Based on SEC 10-K filings.
$796M in FY2025. Top quartile in the Health Care sector.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 148This company $796.3M Sector average $1.2B
▼
-32.3% below sector average
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $796.3M | - |
| FY2024 | - | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026